
Adriana C. Rossi MD
Hematologic Oncology
Assistant Professor of Medicine
Join to View Full Profile
Mount Sinai School Of Medicine Of New York University One Gustav1 Gustave L Levy PlNew York, NY 10029
Dr. Rossi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2010 - 2013
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2007 - 2010
- George Washington University School of Medicine and Health SciencesClass of 2007
Certifications & Licensure
- FL State Medical License 2022 - Present
- NY State Medical License 2010 - 2025
- PA State Medical License 2007 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- BiRd vs. Rd as Initial Therapy in Multiple Myeloma Start of enrollment: 2016 Feb 01
- Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) Start of enrollment: 2018 Oct 23
- Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsExtramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma.Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng, Weijia Fu, Erin Moshier
Bone Marrow Transplantation. 2025-08-01 - Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel F Grajales-Cruz, Jack Khouri
Blood Advances. 2025-07-22 - 1 citationsLong-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje
Journal of Clinical Oncology. 2025-06-03
Press Mentions
- Care Partners for CAR T-cell Therapy in Multiple MyelomaJuly 8th, 2025
- Mount Sinai Highlights Key Updates and Trends for Multiple Myeloma Awareness Month 2025March 3rd, 2025
- Frontline Myeloma Treatments: ASCT vs. CAR TOctober 25th, 2023
- Join now to see all
Professional Memberships
- Member
- Member
- International Kidney and Monoclonal Gammopathy Research GroupMember
- International Myeloma SocietyMember
Other Languages
- Portuguese, Spanish, French, Italian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: